Skip to content
AASLD Family of Websites: Liver Fellow Network
AASLD.org AASLD Foundation LiverLearning Career Center Journals The Liver Meeting HCV Guidelines
AASLD Logo
AASLD Logo

LFN Main Navigation

  • Topics
    Acute Liver Failure Alcohol-Associated Liver Disease Autoimmune Hepatitis Career Development and Mentorship Cholestatic Liver Disease Complications of Liver Disease and Portal Hypertension Drug-Induced Liver Disease HepMadness Inherited Disorders Liver Anatomy, Development, and Physiology Liver Infections Liver Physiology Liver Related Infections MASLD/MASH Neoplasms of the Liver Pathology Pediatrics Pregnancy-Related Liver Disease Symptoms and Clinical Presentation of Liver Disease and Portal HTN Systemic Conditions with Hepatic Manifestations Transplantation and Surgery Vascular Viral Hepatitis
  • Core Series
    Back to Basics Clinical Pearls Webinars Evidence Corner Pathology Pearls Podcast The Why? Series Tools of the Trade View All Core Series Practice Questions
  • Tweetorials
  • About
  • Core Series
  • Evidence Corner
  • A New Second-line Therapy For Primary Biliary Cholangitis: Elafibranor

A new second-line therapy for Primary Biliary Cholangitis: Elafibranor

December 13, 2024

John Esli Medina Morales

Share

Copy Link Twitter Facebook

https://www.nejm.org/doi/full/10.1056/NEJMoa2306185

Cholestatic Liver Disease

Share

Copy Link Twitter Facebook

Written By:

John Esli Medina Morales

Related Content

SCOPE Index

October 23, 2022

Do Steroids Improve Outcomes After Kasai Hepatoportoenterostomy

September 13, 2022

Medical Therapies in Alagille Syndrome

April 18, 2022

AASLD LFN Logo

Follow Us

Disclaimer & Privacy Policy

© 2025 American Association for the Study of Liver Diseases